EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers

Marta Persson, Mattias K Andersson iD, Per-Erik Sahlin, Yoshitsugu Mitani iD, Margaret S Brandwein-Weber, Henry F Frierson, Christopher Moskaluk, Isabel Fonseca, Renata Ferrarotto, Werner Boecker, Thomas Loening, Adel K El-Naggar and 1 more

The Journal of Pathology · 2023-11 · 261 (3) · 256-268

DOI: 10.1002/path.6172 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2023-08-11. Written by Marta Persson and 12 co-authors. Institution: Sahlgrenska Center for Cancer Research, Department of Pathology, University of Gothenburg, Gothenburg, Sweden. Major MEDLINE topics: Carcinoma, Adenoid Cystic, Head and Neck Neoplasms. Cited 16 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cancerfonden, Kungl. Vetenskaps- och Vitterhets-Samhället i Göteborg.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Adenoid cystic carcinoma (ACC) is a MYB‐driven head and neck malignancy with high rates of local recurrence and distant metastasis and poor long‐term survival. New effective targeted therapies and clinically useful biomarkers for patient stratification are needed to improve ACC patient survival. Here, we present an integrated copy number and transcriptomic analysis of ACC to identify novel driver genes and prognostic biomarkers. A total of 598 ACCs were studied. Clinical follow‐up was available from 366 patients, the largest cohort analyzed to date. Copy number losses of 1p36 (70/492; 14%) and of the tumor suppressor gene PARK2 (6q26) (85/343; 25%) were prognostic biomarkers; patients with concurrent losses ( n = 20) had significantly shorter overall survival (OS) than those with one or no deletions ( p < 0.0001). Deletion of 1p36 independently predicted short OS in multivariate analysis ( p = 0.02). Two pro‐apoptotic genes, TP73 and KIF1B , were identified as putative 1p36 tumor suppressor genes whose reduced expression was associated with poor survival and increased resistance to apoptosis. PARK2 expression was markedly reduced in tumors with 6q deletions, and PARK2 knockdown increased spherogenesis and decreased apoptosis, indicating that PARK2 is a tumor suppressor in ACC. Moreover, analysis of the global gene expression pattern in 30 ACCs revealed a transcriptomic signature associated with short OS, multiple copy number alterations including 1p36 deletions, and reduced expression of TP73 . Taken together, the results indicate that TP73 and PARK2 are novel putative tumor suppressor genes and potential prognostic biomarkers in ACC. Our studies provide new important insights into the pathogenesis of ACC. The results have important implications for biomarker‐driven stratification of patients in clinical trials. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Adenoid CysticHead and Neck NeoplasmsHumansPrognosisGenes, Tumor SuppressorTranscriptomeBiomarkers, Tumor

Author keywords

1p deletion6q26 deletionMYBPARK2TP73adenoid cystic carcinomagenomic profilingprognostic biomarkertranscriptomic profilingtumor suppressor gene

Substances

Biomarkers, Tumor

Authors and institutions

  • Sahlgrenska Center for Cancer Research, Department of Pathology, University of Gothenburg, Gothenburg, Sweden.
  • Department of Plastic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
  • Serviço de Anatomia Patológica, Instituto Português de Oncologia de Francisco Gentil - Lisboa and Instituto de Anatomia Patológica, Faculdade de Medicina de Lisboa, Lisbon, Portugal.

ORCID profiles: Mattias K Andersson, Yoshitsugu Mitani, Göran Stenman

Funding

  • Cancerfonden
  • Kungl. Vetenskaps- och Vitterhets-Samhället i Göteborg

Cite

APA

Persson, M., Andersson, M. K., Sahlin, P. E., Mitani, Y., Brandwein-Weber, M. S., Frierson, H. F., Moskaluk, C., Fonseca, I., Ferrarotto, R., Boecker, W., Loening, T., El-Naggar, A. K., & Stenman, G. (2023). Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. The Journal of Pathology, 261(3), 256-268. https://doi.org/10.1002/path.6172

Vancouver

Persson M, Andersson MK, Sahlin PE, Mitani Y, Brandwein-Weber MS, Frierson HF, et al. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. The Journal of Pathology. 2023;261(3):256-268. doi:10.1002/path.6172

BibTeX
@article{Persson2023,
  author = {Persson, Marta and Andersson, Mattias K and Sahlin, Per-Erik and Mitani, Yoshitsugu and Brandwein-Weber, Margaret S and Frierson, Henry F and Moskaluk, Christopher and Fonseca, Isabel and Ferrarotto, Renata and Boecker, Werner and Loening, Thomas and El-Naggar, Adel K and Stenman, Göran},
  title = {Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers},
  journal = {The Journal of Pathology},
  year = {2023},
  volume = {261},
  number = {3},
  pages = {256--268},
  doi = {10.1002/path.6172}
}
Start for free →